Free Trial
NASDAQ:IRON

Disc Medicine Q3 2023 Earnings Report

Disc Medicine logo
$47.98 -1.54 (-3.10%)
As of 10:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Disc Medicine EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.75
Beat/Miss
Beat by +$0.17
One Year Ago EPS
N/A

Disc Medicine Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Disc Medicine Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Disc Medicine's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Tuesday, May 13, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Disc Medicine Earnings Headlines

Disc Medicine: Forging Ahead In Hematology
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
See More Disc Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Disc Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Disc Medicine and other key companies, straight to your email.

About Disc Medicine

Disc Medicine (NASDAQ:IRON), together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

View Disc Medicine Profile

More Earnings Resources from MarketBeat